Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO
Summary
The company has completed preclinical studies successfully demonstrating receptor-mediated delivery of oligonucleotides to the kidney with proprietary ligand-siRNA conjugates that silence multiple target genes. The proceeds from the financing will be used to advance the lead ligand-siRNA conjugate to the clinic and to further build the companys proprietary STRIKE (Selectively Targeting RNA Into KidnEy) platform. Judo Bios initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule epithelial cells of the kidney. In a short period, the company has developed a novel platform, demonstrated potent and selective gene knockdown in specific kidney regions, and constructed a pipeline of compelling programs that we are excited to see advanced towards the clinic. Previously, he served as Chief Medical Officer at several successful public small-cap biotech companies, including Global Blood Therapeutics and Portola Pharmaceuticals.